Management of non-metastatic castrate-resistant prostate cancer: A systematic review.
Fiche publication
Date publication
septembre 2018
Journal
Cancer treatment reviews
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Loriot Y, Supiot S, Beauval JB, Schlürmann F, Pasticier G, Sargos P, Barthélémy P, Pignot G, Maillet D, Vincendeau S, Gross E, Ploussard G, Timsit MO, Borchiellini D
Lien Pubmed
Résumé
Management of non metastatic castrate resistant prostate cancer is challenging for clinicians due to the heterogeneity of the disease and to the scarce clinical data available in this setting. Recent results obtained with the new generation hormone therapies (NGHT) apalutamide and enzalutamide bring a new perspective for the treatment strategy. The authors present here a systematic review of the treatment options.
Mots clés
Castration-resistant, Hormone therapies, Non-metastatic, Prostate cancer, nmCRPC
Référence
Cancer Treat. Rev.. 2018 Sep 21;70:223-231